secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phathom Pharmaceuticals, Inc. (PHAT)
CIK:        0001783183
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001193125-24-196506
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phathom Q2 revenue $7.3M, prescriptions up 184%; VOQUEZNA gets FDA approval for Non-Erosive GERD
--------------------------------------------------------------------------------

- Net revenues $7.3M in Q2 2024 vs $1.9M in Q1 2024; no Q2 2023 revenue due to launch in late 2023.
- Over 122,000 cumulative prescriptions written (184% increase from 43,000); over 60,000 filled (240% from 17,500).
- FDA approved VOQUEZNA 10mg for Non-Erosive GERD on July 18; commercial coverage now >116M lives (77% of US commercial).
- Net loss $91.4M; non-GAAP adjusted net loss $73.3M; SG&A rose to $75.9M on launch commercialization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783183/000119312524196506/0001193125-24-196506-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783183/000119312524196506/d834335d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-196506

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer